


Jidong Zhao¹, Binyuan Sun², Xuefei Yi¹, Qiang Peng¹, Shuangshaung Ping¹, Xiaoli Kan², Xiaoxia Wang², Song Liang¹, Yang Wang² and Weibin Chen¹ ¹Shanghai Asymchem Biotechnology Co., Ltd, 4th Floor, Building No. 1, 518 Haoye Road, Jinshan Industrial Park, Jinshan, Shanghai, China ²NovacyteTherapeutics Hangzhou Co., Ltd., Room 702-1,No. 858 Mogan Mountain Road, Hangzhou, Zhejiang, China

Summary

NC18 ADC utilizes a polymer-based linker to afford high drug-to-antibody ratio (DAR>10) and significantly improves its potency, bystander effect and anti-drug resistance performance. As an effort to deliver high-quality NC18 materials, we carefully optimized the polymer-based conjugation process and developed a novel analytical method for DAR analysis.



- AF-HEA cytotoxic payload
- A polymeric linker design
- Controllable bystander effect & superior PK profile

Conjugation Process Optimization


뵺 payload

Charge group Maleimide group MI: percentage of maleimide

PI: percentage of payload

Challenge: The heterogeneity(MI & PI) of the polymer-based payload-linker (PL) structures poses challenges to generate consist batch-to-batch materials.

Our solution: DoE experiments to evaluate the PL molecular weight, MI/PI, and the mass ratio between mAb and the PL were performed to acquire the optimized process space with the improved performance to assure the batch-to-batch **Consistent product quality at** consistency.



Design, Synthesis and Evaluation of a Novel Antibody-Drug Conjugate based on Cysteine **Conjugation and a Polymer Linker**

